Trending News Today: Federal Funding Contributes to Large Number of Drug Approvals

President Donald Trump’s fiscal year 2019 budget request may begin to address high drug costs, but it might not be enough to actually lower prices, Kaiser Health News reported. The proposed budget seeks to cut billions from Medicare funding and changes drug spending in Medicaid. While the cuts will have a big impact due to the magnitude of these safety net programs, the changes may not be groundbreaking, and addressing the underlying issue of high drug costs will be key, according to the article.

A recent study found that federal research funding contributed to the approval of 210 drugs between 2010 and 2016, highlighting the importance of spending on scientific research, according to STAT. The authors found that more than $100 billion in funding from the National Institutes of Health contributed to these approvals, accounting for approximately 20% of the agency’s spending since 2000. Notably, more than $64 billion contributed to the approval of 84 drugs that were first-in-class, which treat diseases through new mechanisms or targets, according to the article.

Growing evidence suggests that ovarian cancer may begin in the fallopian tubes, not the ovaries, according to The Wall Street Journal. Currently, there is no effective way to screen for ovarian cancer and it typically is not diagnosed until later stages when it has metastasized. Understanding where the disease starts may lead to better ovarian cancer prevention and treatment strategies, according to the article.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.
Top news of the week from Specialty Pharmacy Times.
The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.